You are here: Industry Insights > Market News

News List

MIMETAS Contributes With Human Organ-on-Chip Data to IND Application by Argenx Biotech Newswire
July 12, 2024
MIMETAS announced an Investigational New Drug (IND) filing by argenx and was supported by data from MIMETAS.
AzarGen Presents AZprom™ - Superior Synthetic Promotors to Enhance Molecular Farming Applications Biotech Newswire
July 10, 2024
AzarGen presents AZprom™ - Superior Synthetic Promotors and it shows a dramatic increase in the expression of fluorescent proteins, outperforming the ‘double-enhancer’ CaMV 35S promoter more than 5-fold in transgenic tobacco plants.
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases Biotech Newswire
July 09, 2024
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy.
Eleva Receives Orphan Drug Designation in Europe for Proprietary Factor H Therapy in C3 Glomerulopathy (C3G) Biotech Newswire
July 04, 2024
Eleva announced that the European Commission has granted the Orphan Drug Designation for Factor H (CPV-104), the company’s recombinant version of human complement Factor H, to treat C3 Glomerulopathy (C3G).
Touchlight and LenioBio Collaborate to Accelerate Development of Protein Therapeutics for Pandemic Response Biotech Newswire
July 03, 2024
Touchlight and LenioBio collaborate deeply to further demonstrate the breadth of dbDNA applications.
Celonic Inaugurates “Next Generation” Biologics Development Center (BDC) and Pilot Plant in Basel, Switzerland Biotech Newswire
June 24, 2024
The Celonic Group, a Swiss Based Quality Biologics Contract Development and Manufacturing Organization (CDMO) today opened its “Next Generation” Biologics Development Center and Pilot Plant in Basel, Switzerland.
NXI Therapeutics Extends Pre-Seed Financing to CHF 3.5 Million in Run-up to Larger Seed Financing Biotech Newswire
June 24, 2024
NXI Therapeutics AG, developer of tomorrow’s disruptive immunotherapies by coronin 1 modulation, today announces the extension of a pre-Seed financing totalling to 3.5 million CHF.
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress PharmaSources
June 14, 2024
Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA PharmaSources
June 11, 2024
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) ap
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress PharmaSources
June 05, 2024
Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)